In 2023, Werewolf Therapeutics, Inc. anticipated multiple catalysts as the company progress the company's two clinical stage programs, WTX-124 and WTX-330, through first in human testing and expect to share initial clinical data on the safety, tolerability, and preliminary efficacy of WTX-124 in the fourth quarter. Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in fourth quarter of 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.49 USD | -0.29% | -32.50% | -9.59% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.59% | 152M | |
+51.85% | 59.28B | |
+41.42% | 40.94B | |
-5.25% | 40.17B | |
-5.16% | 28.69B | |
+12.79% | 26.63B | |
-20.18% | 18.89B | |
+30.88% | 12.46B | |
+0.61% | 12.42B | |
+25.06% | 12.26B |
- Stock Market
- Equities
- HOWL Stock
- News Werewolf Therapeutics, Inc.
- Werewolf Therapeutics, Inc. Anticipates Multiple Catalysts as the Company Progress the Company's Two Clinical Stage Programs, WTX-124 and WTX-330